Stage-dependent prognostic value of programmed death ligand-1 expression in gastric cancer: Implications for personalized immunotherapy

doi:10.3748/wjg.118762

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 34

This Article

(5)

(0)

(35)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Opinion Review

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. Sep 14, 2026; 32(34): 118762
Published online Sep 14, 2026. doi: 10.3748/wjg.118762

Table 1 Representative phase III trials of immune checkpoint inhibitors in perioperative and advanced gastric cancer

Trial name	Phase	Patient population	Treatment arms (intervention vs control)	PD-L1 cut-off (CPS)	Primary endpoint/result	Ref.
KEYNOTE-585	III	Perioperative (LAGC)	Pembro + Chemo vs Placebo + Chemo	Analysis ≥ 1, ≥ 10	pCR: Significantly improved; EFS/OS: Not met in the overall population	Shitara et al[52], 2024
MATTERHORN	III	Perioperative (LAGC)	Durva + FLOT vs Placebo + FLOT	All comers	pCR: Significantly improved (19% vs 7%); EFS: Significantly improved (HR 0.71); OS immature	Janjigian et al[53], 2025
CheckMate 649	III	Advanced (1st line)	Nivo + Chemo vs Chemotherapy alone	≥ 5, ≥ 1	OS and PFS: Significantly improved in CPS ≥ 5 (standard of care)	Janjigian et al[44], 2021
KEYNOTE-062	III	Advanced (1st line)	Pembro ± Chemo vs Chemotherapy alone	≥ 1, ≥ 10	OS: Pembro monotherapy non-inferior to chemo (CPS ≥ 1); combination failed superiority	Shitara et al[43], 2020
ATTRACTION-4	III	Advanced (1st line)	Nivo + Chemo vs Placebo + Chemo	All comers	PFS: Significantly improved; OS: Not met	Kang et al[46], 2022

CPS: Combined Positive Score; EFS: Event-free survival; LAGC: Locally advanced gastric cancer; OS: Overall survival; pCR: Pathological complete response; PFS: Progression-free survival; FLOT: Fluorouracil + leucovorin + oxaliplatin + docetaxel; Pembro: Pembrolizumab; Chemo: Chemotherapy; Durva: Durvalumab; Nivo: Nivolumab.

Full Size Table

Citation: Takahashi K. Stage-dependent prognostic value of programmed death ligand-1 expression in gastric cancer: Implications for personalized immunotherapy. World J Gastroenterol 2026; 32(34): 118762
URL: https://www.wjgnet.com/1007-9327/full/v32/i34/118762.htm
DOI: https://dx.doi.org/10.3748/wjg.118762

Takahashi K. Stage-dependent prognostic value of programmed death ligand-1 expression in gastric cancer: Implications for personalized immunotherapy. World J Gastroenterol 2026; 32(34): 118762 [DOI: 10.3748/wjg.118762]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.